Uremic toxin development in living kidney donors: A longitudinal study

Transplantation

Volumn 97, Issue 5, 2014, Pages 548-554

  Rossi, Megan ^a,b,c   Campbell, Katrina L ^a,b,c   Johnson, David W ^a,b,c   Stanton, Tony ^a,b   Haluska, Brian A ^b   Hawley, Carmel M ^a,b   Dimeski, Goce ^a   McWhinney, Brett C ^d   Ungerer, Jacobus P J ^d   Kaisar, Omar M ^a   Isbel, Nicole M ^a,b  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c TRANSLATIONAL RESEARCH INSTITUTE   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Cardiovascular risk; Indoxyl sulfate; Living kidney donor; Nephrectomy; P Cresyl sulfate

Indexed keywords

C REACTIVE PROTEIN; CREATININE; CYSTATIN C; INDICAN; PARA CRESYL SULFATE; UNCLASSIFIED DRUG; UREMIC TOXIN; URIC ACID;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD VESSEL REACTIVITY; BRACHIAL ARTERY; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; COHORT ANALYSIS; FEMALE; HUMAN; KIDNEY DONOR; KIDNEY FUNCTION; LIVING DONOR; LONGITUDINAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RISK FACTOR; URIC ACID BLOOD LEVEL;

ADULT; BIOLOGICAL MARKERS; CRESOLS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; INDICAN; KIDNEY; KIDNEY TRANSPLANTATION; LIVING DONORS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEPHRECTOMY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SULFURIC ACID ESTERS; UREMIA;

EID: 84896314768     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000436906.48802.c4     Document Type: Article

References (57)

1. Schepers E, Glorieux G, Vanholder R. The gut: The forgotten organ in uremia? Blood Purif 2010; 29: 130
2. Motojima M, Hosokawa A, Yamato H, et al. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney Int 2003; 63: 1671
3. Lekawanvijit S, Adrahtas A, Kelly DJ, et al. Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur Heart J 2010; 31: 1771
4. Watanabe H, Miyamoto Y, Otagiri M, et al. Update on the pharmacokinetics and redox properties of protein-bound uremic toxins. J Pharm Sci 2011; 100: 3682
5. Sun CY, Chang SC, Wu MS. Uremic toxins induce kidney fibrosis by activating intrarenal renin-Angiotensin-Aldosterone system associated epithelial-To-mesenchymal transition. PLoS One 2012; 7: E34026
6. Adijiang A, Goto S, Uramoto S, et al. Indoxyl sulphate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats. Nephrol Dial Transplant 2008; 23: 1892
7. Wu IW, Hsu KH, Lee CC, et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant 2010; 26: 938
8. Lin CJ, Liu HL, Pan CF, et al. Indoxyl sulfate predicts cardiovascular disease and renal function deterioration in advanced chronic kidney disease. Arch Med Res 2012; 43: 451
9. Meijers BKI, Bammens B, De Moor B, et al. Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 2008; 73: 1174
10. Barreto FC, Barreto DV, Liabeuf S, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4: 1551
11. Bammens B, Evenepoel P, Keuleers H, et al. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 2006; 69: 1081
12. Liabeuf S, Barreto DV, Barreto FC, et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 2010; 25: 1183
13. Organ Procurement and Transplantation Network(OPTN). National Data, Transplants by Donor Type. U.S. Department of Health & Human Services.Accessed March 1st 2013
14. Clayton P, Campbell SB, Hurst K, et al. Australian and New Zealand Dialysis and Transplant Registry Annual Report-Transplantation ANZDATA, 2011
15. Gourishankar S, Courtney M, Jhangri GS, et al. Serum cystatin C performs similarly to traditional markers of kidney function in the evaluation of donor kidney function prior to and following unilateral nephrectomy. Nephrol Dial Transplant 2008; 23: 3004
16. Fehrman-Ekholm I, Duner F, Brink B, et al. No evidence of accelerated loss of kidney function in living kidney donors: Results from a crosssectional follow-up. Transplantation 2001; 72: 444
17. Goldfarb DA, Matin SF, Braun WE, et al. Renal outcome 25 years after donor nephrectomy. J Urol 2001; 166: 2043
18. Ibrahim HN, Rogers T, Tello A, et al. The performance of three serum creatinine-based formulas in estimating GFR in former kidney donors. Am J Transplant 2006; 6: 1479
19. Gossmann J, Wilhelm A, Kachel HG, et al. Long-Term consequences of live kidney donation follow-up in 93% of living kidney donors in a single transplant center. Am J Transplant 2005; 5: 2417
20. Garg AX, Muirhead N, Knoll G, et al. Proteinuria and reduced kidney function in living kidney donors: A systematic review, meta-Analysis, and meta-regression. Kidney Int 2006; 70: 1801
21. KDIGO. KDIGO 2012 clinial practice guidelines for the evaluation and management of chronic kidney disease. Kidney Int 2013; 3
22. Boudville N, Prasad GV, Knoll G, et al. Meta-Analysis: Risk for hypertension in living kidney donors. Ann Intern Med 2006; 145: 185
23. Lentine KL, Patel A. Risks and outcomes of living donation. Adv Chronic Kidney Dis 2012; 19: 220
24. SegevDL,Muzaale AD, Caffo BS, et al. Perioperative mortality and longterm survival following live kidney donation. JAMA 2010; 303: 959
25. Kaisar MO, Nicol DL, Hawley CM, et al. Change in live donor characteristics over the last 25 years: A single centre experience. Nephrology 2008; 13: 646
26. Mandelbrot DA, Pavlakis M. Living donor practices in the United States. Adv Chronic Kidney Dis 2012; 19: 212
27. Meijers BKI, Evenepoel P. The gut-kidney axis: Indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrol Dial Transplant 2011; 26: 759
28. Fukuuchi F, Hida M, Aiba Y, et al. Intestinal bacteria-derived putrefactants in chronic renal failure Clin Exp Nephrol 2002; 6: 99
29. Duranton F, Cohen G, De Smet R, et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol 2012; 23: 1258
30. Eloot S, Schepers E, Barreto DV, et al. Estimated glomerular filtration rate is a poor predictor of concentration for a broad range of uremic toxins. Clin J Am Soc Nephrol 2011; 6: 1266
31. Lin CJ, Pan CF, Liu HL, et al. The role of protein-bound uremic toxins on peripheral artery disease and vascular access failure in patients on hemodialysis. Atherosclerosis 2012; 225: 173
32. Chiu CA, Lu LF, Yu TH, et al. Increased levels of total p-cresylsulphate and indoxyl sulphate are associated with coronary artery disease in patients with diabetic nephropathy. Rev Diabet Stud 2010; 7: 275
33. Yu M, Kim YJ, Kang DH. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin J Am Soc Nephrol 2011; 6: 30
34. Iida S, Kohno K, Yoshimura J, et al. Carbonic-Adsorbent AST-120 reduces overload of indoxyl sulfate and the plasma level of TGFbeta1 in patients with chronic renal failure. Clin Exp Nephrol 2006; 10: 262
35. Srinivas TR, Poggio ED. Do living kidney donors have CKD? Adv Chronic Kidney Dis 2012; 19: 229
36. World Health Organisation (WHO). Waist Circumference and Waist-Hip Ratio Report of a WHO Expert Consultation. Geneva: WHO; 2008
37. Vanholder R, Abou-Deif O, Argiles A, et al. The role of EUTox in uremic toxin research. Semin Dial 2009; 22: 323
38. Rossi M, Klein K, Johnson DW, et al. Pre-, pro-, and synbiotics: Do they have a role in reducing uremic toxins? A systematic review and meta-Analysis. Int J Nephrol 2012; 2012: 673631
39. Pretorius CJ,McWhinney BC, Sipinkoski B, et al. Reference ranges and biological variation of free and total serum indoxyl-And p-cresyl sulphatemeasured with a rapid UPLC fluorescence detection method. Clin Chim Acta 2013; 419: 122
40. Aronov PA, Luo FJ-G, Plummer NS, et al. Colonic contribution to uremic solutes. J Am Soc Nephrol 2011; 22: 1769
41. Lin CJ, Chen HH, Pan CF, et al. p-Cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease. J Clin Lab Anal 2011; 25: 191
42. Bahous SA, Stephan A, Blacher J, et al. Aortic stiffness, living donors, and renal transplantation. Hypertension 2006; 47: 216
43. Howard G, Sharrett AR, Heiss G, et al. Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound. ARIC Investigators. Stroke 1993; 24: 1297
44. Davis CL. Living kidney donor follow-up: State-of-The-Art and future directions. Adv Chronic Kidney Dis 2012; 19: 207
45. McDonald S, Excell L, Livingston B. Australian and New Zealand Dialysis and Transplant Registry Annual Report-Transplantation: ANZDATA. 2006
46. Ferrari P, Fidler S, Woodroffe C, et al. Comparison of time on the deceased donor kidney waitlist versus time on the kidney paired donation registry in the Australian program. Transpl Int 2012; 25: 1026
47. Nogueira JM, Weir MR, Jacobs S, et al. A study of renal outcomes in obese living kidney donors. Transplantation 2010; 90: 993
48. Lafranca J, Hagen S, Dols L, et al. Systematic review and meta-Analysis of the relation between body mass index and short-Term donor outcome of laparoscopic donor nephrectomy. Kidney Int 2013; 83: 931
49. Poggio ED, Rule AD, Tanchanco R, et al. Demographic and clinical characteristics associated with glomerular filtration rates in living kidney donors. Kidney Int 2009; 75: 1079
50. Enomoto A, Niwa T. Roles of organic anion transporters in the progression of chronic renal failure. Ther Apher Dial 2007; 11: S27
51. Jalal DI, Chonchol M, Chen W, et al. Uric acid as a target of therapy in CKD. Am J Kidney Dis 2013; 61: 134
52. The Transplantation Society of Australian and New Zealand (TSANZ). Kidney ProtocolVThe Allocation of Transplant Kidneys in Australia. TSANZ, Sydney, Australia: 2011
53. Grubb A, Blirup-Jensen S, Lindstrom V, et al. First certified reference material for cystatin C in human serum ERM-DA471/IFCC. Clin Chem Lab Med 2010; 48: 1619
54. Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012; 367: 20
55. Masson I, Maillard N, Tack I, et al. GFR estimation using standardized cystatin C in kidney transplant recipients. Am J Kidney Dis 2013; 61: 279
56. Physical status: The use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1995; 854: 1
57. Gerhard-Herman M, Gardin JM, Jaff M, et al. Guidelines for noninvasive vascular laboratory testing: A report from the American Society of Echocardiography and the Society for Vascular Medicine and Biology. Vasc Med 2006; 11: 183